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The Tokyo Guidelines 2018 (TG18) recommend emergent cholecystectomy (EC) for acute cholecystitis. 
However, the number of patients on antithrombotic therapy (AT) has increased significantly, and no 
evidence has yet suggested that EC should be performed for acute cholecystitis in such patients. The 
aim of this study was to evaluate whether EC is as safe for patients on AT as for patients not on AT. 
We retrospectively analyzed patients who underwent EC from 2007 to 2018 at a single center. First, 
patients were divided into two groups according to the use of antithrombotic agents: AT; and no-AT. 
Second, the AT group was divided into three sub-groups according to the use of single antiplatelet 
therapy (SAPT), double antiplatelet therapy (DAPT), or anticoagulant with or without antiplatelet 
therapy (AC ± APT). We then evaluated outcomes of EC among all four groups. The primary outcome 
was 30- and 90- day mortality rate, and secondary outcomes were morbidity rate and surgical 
outcomes. A total of 478 patients were enrolled (AT, n = 123, no-AT, n = 355) patients. No differences 
in morbidity rate (6.5% vs. 3.7%, respectively; P = 0.203), 30-day mortality rate (1.6% vs. 1.4%, 
respectively; P = 1.0) or 90-day mortality rate (1.6% vs. 1.4%, respectively; P = 1.0) were evident 
between AT and no-AT groups. Between the no-AT and AC ± APT groups, a significant difference was 
seen in blood loss (10 mL vs. 114 mL, respectively; P = 0.017). Among the three AT sub-groups and the 
no-AT group, no differences were evident in morbidity rate (3.7% vs. 8.9% vs. 0% vs. 6.5%, respectively; 
P = 0.201) or 30-day mortality (1.4% vs. 0% vs. 0% vs. 4.3%, respectively; P = 0.351). No hemorrhagic or 
thrombotic morbidities were identified after EC in any group. In conclusion, EC for acute cholecystitis is 
as safe for patients on AT as for patients not on AT.
Acute cholecystitis is a common disease causing acute abdomen. The Tokyo Guidelines 2018 (TG18), as interna-
tional practice guidelines for the management of patients with acute cholecystitis, provide diagnostic criteria, a 
severity grading scale, and a flowchart for the treatment of acute cholecystitis1. TG18 recommend early or emer-
gent laparoscopic cholecystectomy (LC) as the first-choice treatment for Grade I (mild), Grade II (moderate) and 
Grade III (severe) acute cholecystitis under strict criteria2.
In recent years, the number of patients on antithrombotic therapy (AT) has increased significantly3. The bene-
ficial effects of AT for patients with cardiovascular and cerebrovascular diseases have been established. Generally, 
in elective non-cardiac surgery, AT is interrupted or changed before surgery. Some reports have described the 
management of AT among patients undergoing invasive procedures3. Administration of reversal agents to 
patients taking anticoagulants has been recommended for emergent procedures. However, no evidence has yet 
been provided to suggest that emergent cholecystectomy (EC) should be performed for acute cholecystitis in 
patients on AT. Although early LC in patients with acute cholecystitis is well known to show good results4,5, cli-
nicians often interrupt AT and do not perform EC until antithrombotic effects disappear. Delays in EC are asso-
ciated with perioperative complications, longer hospital stay and higher hospital costs6. We have reported on the 
feasibility and safety of EC in patients on AT in a small number of cases7, but no evidence-based guidelines have 
yet been devised to define the optimal timing of EC in patients on AT for acute cholecystitis.
The aim of this study was to evaluate whether EC can be performed as safely in patients on AT as in patients 
not on AT.
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Methods
This was a retrospective study at a single center. Patients were diagnosed with acute cholecystitis in accordance 
with TG18 criteria2. All patients underwent computed tomography (CT) before emergent surgery. Magnetic res-
onance cholangiopancreatography (MRCP) was performed on patients who could keep sufficiently still (n = 438). 
In our institution, regardless of the severity of acute cholecystitis, when a patient can tolerate general anesthesia 
and agrees to emergent surgery, EC is performed as soon as possible. On the other hand, patients with severe 
respiratory failure, heart failure or valvular disease who cannot undergo general anesthesia instead receive gall-
bladder drainage.
We defined AT as the use of aspirin, warfarin, clopidogrel, cilostazol, ticlopidine, apixaban, dabigatran, edox-
aban or rivaroxaban. If patients on warfarin therapy showed a prothrombin time-international normalized ratio 
(PT-INR) > 1.5, vitamin K or fresh frozen plasma (FFP) was injected before the surgery to reverse any anticoag-
ulant effects. Other patients with acute cholecystitis underwent EC as soon as possible without discontinuation 
of AT.
Patients who had cholangitis or urinary tract infection were excluded from this investigation.
The following data were recorded: age, sex, presence of gallstones, severity of acute cholecystitis, time from 
onset to surgery, laboratory data (white blood cells (WBC); hemoglobin (Hb); platelets (Plt); PT-INR; C-reactive 
protein (CRP); serum total bilirubin (T-Bil); and creatinine (Cr)), American Society of Anesthesiologists (ASA) 
score, operation time, intraoperative blood loss, rate of intraoperative red blood cell (RBC) transfusion, rate of 
laparoscopic surgery, morbidity (Clavien-Dindo classification (CD) Grade≥ IIIa), length of hospital stay and 
30- and 90-day mortality rate.
First, patients were divided into two groups: patients on AT; and patients not on AT. We compared the out-
comes of EC between these two groups. Second, as antithrombotic effects may differ between agents, such as anti-
coagulant therapy (ACT) and antiplatelet therapy (APT), the AT group was divided into three subgroups: single 
APT (SAPT); double APT (DAPT); and anticoagulant with or without antiplatelet therapy (AC ± APT). We then 
compared outcomes of EC between the four groups (no-AT vs. SAPT vs. DAPT vs. AC ± APT). The primary out-
comes were 30- and 90-day mortality rates, and secondary outcomes were morbidity rate and surgical outcomes.
All statistical analyses were performed using EZR version 1.33 (Saitama Medical Center, Jichi Medical 
University, Saitama, Japan), a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, 
Austria). More precisely, EZR is a modified version of R Commander designed to add statistical functions fre-
quently used in biostatistics8. Fisher’s exact test and Bonferroni correction were used for comparing categori-
cal variables. Continuous variables were analyzed using the Mann-Whitney U test and multiple comparisons 
were performed using the Kruskal-Wallis and Steel-Dwass tests. Values of P < 0.05 were considered statistically 
significant.
All study protocols were approved by the ethics committee at Fukuyama City Hospital (permission number 
268). The ethics committee determined this study was a retrospective observational study based on patient charts, 
and thus informed patient consent was therefore not required. All procedures in this study were performed in 
accordance with the relevant guidelines and regulations. Our study was carried out using the opt-out method of 
our institution website.
Results
Between January 2007 and April 2018, a total of 478 patients (AT, n = 123; no-AT, n = 355) were enrolled. 
Table 1 shows the characteristics of overall cases. Significant differences in age (76 years vs. 69 years, respectively; 
P < 0.001), sex (74.0% vs. 62.2%, respectively; P = 0.021), presence of gallstones (76.4% vs. 86.4%, respectively; 
P = 0.015), severity grade I/III (28.5/35.8% vs. 47.6/13.0%, respectively; P < 0.001), ASA score ≥ 3 (58.5% vs. 
34.1%, respectively; P < 0.001), Hb (12.8 mg/dl vs. 13.7 mg/dl, respectively; P < 0.001), Cr (0.9 mg/dl vs. 0.8 mg/dl, 
respectively; P < 0.001) and PT-INR (1.2 vs. 1.1, respectively; P < 0.001) were identified between the two groups.
Table 2 shows the details of the antithrombotic agents administered. Of the 123 patients in AT group, 41 had 
taken aspirin alone, 31 had taken warfarin alone and 17 patients had taken aspirin and clopidogrel. Many of the 
indications for AT were atrial fibrillation or ischemic heart disease (Table 3).
Surgical outcomes for the AT and the no-AT groups are summarized in Table 4. Significant differences were 
seen in median blood loss (80 mL vs. 10 mL, respectively; P = 0.005), rate of RBC transfusion (8.1% vs. 2.5%, 
respectively; P = 0.013) and median hospital stay (7 days vs. 6 days, respectively; P < 0.001). No differences 
were evident in median operation time (110 min vs. 103 min, respectively; P = 0.212), rate of laparoscopic sur-
gery (79.7% vs. 86.2%, respectively; P = 0.111), morbidity rate of CD Grade≥ IIIa (6.5% vs. 3.7%, respectively; 
P = 0.203), 30-day mortality rate (1.6% vs. 1.4%, respectively; P = 1.0) and 90-day mortality rate (1.6% vs. 1.4%, 
respectively; P = 1.0) between these two groups. AT was not a significant factor in 30-day mortality rate in Cox 
proportional hazards regression modeling (P = 0.838).
Table 5 shows the characteristics of the four groups (no-AT, SAPT, DAPT and AC ± APT). Surgical outcomes 
are summarized in Table 6. Figure 1 show multiple comparisons of characteristics and surgical outcomes. Patients 
in the AC ± ATP group included more patients with severity grade III (13% vs. 19.6% vs. 14.3% vs. 65.2%, respec-
tively; P < 0.001) and higher PT-INR (1.1 vs. 1.2 vs. 1.2 vs. 1.7, respectively; P < 0.001) than patients in the other 
groups. Between the no-AT and AC ± APT groups, significant differences were seen in age (69 years vs. 79.5 
years, respectively; P < 0.001), presence of gallstones (86.4% vs. 67.4%, respectively; P = 0.012), severity grade I 
(47.6% vs. 13.0%, respectively; P < 0.001), ASA-PS ≥ 3 (34.1% vs. 76.1%, respectively; P < 0.001), CRP (6.9 mg/dL 
vs. 13.1 mg/dL, respectively; P < 0.001), Cr (0.8 mg/dL vs. 0.9 mg/dL, respectively; P = 0.017), blood loss (10 mL 
vs. 114 mL, respectively; P = 0.017) and length of hospital stay (6 days vs. 8 days, respectively; P < 0.001). RBC 
transfusion rate was higher in the DAPT group than in the no-AT group (2.5% vs. 19%, respectively; P = 0.022). 
No differences were evident in the rate of morbidity and hospital mortality among the four groups.
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Several morbidities occurred in all groups (Table 6). Most morbidities, such as organ dysfunction or 
non-occlusive mesenteric ischemia (NOMI), were caused by sepsis. Three patients who experienced morbidity in 
the AC ± APT group underwent reversal of anticoagulants before EC. No hemorrhagic or thrombotic morbidities 
were identified after EC in any groups.
Seven deaths occurred among all patients: 2 in the AC ± APT group and 5 in the no-AT group. In the AC ± APT 
group, 1 patient died of NOMI caused by superior mesenteric artery stenosis due to arteriosclerosis on postoper-
ative day (POD)19. The other died of acute exacerbation of chronic heart failure on POD7. In the no-AT group, 2 
patients died because of multiple-organ failure (MOF) due to septic acute cholecystitis on POD1 and POD6. One 
patient with post-resuscitation encephalopathy who underwent EC, died because of aspiration pneumonia on 
POD6. Another patient experienced a severe asthma attack triggered by pneumonia and developed respiratory 
failure. He received steroid pulse therapy, but gastrointestinal perforation occurred and he died on POD25. The last 






(n = 355) P
Age, years∗ 76 (47-94) 69 (18-95) <0.001
Male sex (%) 91 (74.0) 221 (62.2) 0.021
Gallstone (%) 94 (76.4) 307 (86.4) 0.015
Onset-surgery (h) 48 (12-288) 48 (12-336) 0.842
Severity grade
I (%) 35 (28.5) 169 (47.6) <0.001
II (%) 44 (35.8) 140 (39.4) 0.519
III (%) 44 (35.8) 46 (13.0) <0.001
ASA-PS ≥ 3 (%) 72 (58.5) 121 (34.1) <0.001
Laboratory data
WBC (×102/µL) 127 (37-472) 114 (17-431) 0.021
Hb (mg/dL) 12.8 (8.3-16.8) 13.7 (6.6-17.6) <0.001
Plt (×104/µL) 18.5 (4.9-52.4) 20.3 (3.1-56.3) 0.066
T-Bil (mg/dL) 1.0 (0.2-14.6) 1.0 (0.2-8.5) 0.701
CRP (mg/dL) 12.1 (0.02-30.6) 6.9 (0.01-50.0) 0.001
Cr (mg/dL) 0.9 (0.30-9.05) 0.8 (0.4-10.1) <0.001
PT-INR 1.2 (0.9-12.4) 1.1 (0.9-1.6) <0.001
Table 1. Overall patient characteristics. Data are presented as the percentage or median value of parameters 
[range]. Severity grade: According to the Tokyo Guidelines 2018 severity grading for acute cholecystitis. ASA, 
American Society of Anesthesiologists; WBC, white blood cells; Hb, hemoglobin; Plt, platelets; T-Bil, total 














Aspirin + apixaban 1
Aspirin + cilostazol 1
Aspirin + dabigatran 1
Aspirin + ticlopidine 1
Clopidogrel + cilostazol 1
Warfarin + cilostazol 1
Warfarin + clopidogrel 1
Table 2. Details of antithrombotic agents.




Ischemic heart disease 35
Ischemic stroke 35
CABG 7
Primary prevention of stroke 6
DVT 5
Mechanical valve replacement 3
PAD 3
Table 3. Indications for antithrombotic therapy. ∗Some patients showed multiple comorbidities. AF, atrial 
fibrillation; CABG, coronary artery bypass grafting; DVT, deep vein thrombosis; PAD, peripheral arterial 
disease
AT (n = 123)
No-AT 
(n = 355) P
Intraoperative
Operation time, min 110 (42-346) 103 (27-263) 0.212
Blood loss, mL 80 (0-2315) 10 (0-4880) 0.005
Laparoscopic surgery (%) 98 (79.7) 306 (86.2) 0.111
RBC transfusion (%) 10 (8.1) 9 (2.5) 0.013
Postoperative
Morbidity (CD grade 
≥IIIa) (%) 8 (6.5) 13 (3.7) 0.203
Length of stay, days 7 (2-55) 6 (1-82) <0.001
30-day mortality (%) 2 (1.6) 5 (1.4) 1.0
90-day mortality (%) 2 (1.6) 5 (1.4) 1.0
Table 4. Perioperative outcomes for AT and no-AT groups. Data are presented as the number of patients (%) or 









(n = 46) P
Age, years∗ 69 (18-98) 77.5 (54-94) 72 (47-80) 76.5 (55-93) <0.001
Male sex (%) 221 (62.2) 38 (67.8) 19 (90.4) 34 (73.9) 0.024
Gallstones (%) 307 (86.4) 49 (87.5) 14 (66.7) 31 (67.4) 0.002
Onset-surgery (h) 48 (12-288) 48 (12-336) 48 (12-144) 48 (12-72) 0.601
Severity grade (%)
I (%) 169 (47.6) 22 (39.3) 7 (33.3) 6 (13.0) <0.001
II (%) 140 (39.4) 23 (41.1) 11 (52.4) 10 (21.7) 0.052
III (%) 46 (13.0) 11 (19.6) 3 (14.3) 30 (65.2) <0.001
ASA-PS ≥ 3 (%) 121 (34.1) 36 (64.3) 18 (85.7) 35 (76.1) <0.001
Laboratory data
WBC (×102/ µL) 114 (17-431) 117 (37-402) 141 (95-281) 131 (42-472) 0.026
Hb (mg/dL) 13.7 (6,6-17.6) 12.7 (8.6-16.8) 12.5 (9.4-15.5) 12.9 (8.3-16.8) <0.001
Plt (×104/µL) 20.3 (3.1-56.3) 20.5 (8.1-52.4) 17.1 (9.7-35.2) 17.3 (4.9-37.9) 0.098
T-Bil (mg/dL) 1.0 (0.2-8.5) 0.8 (0.2-3.8) 1.2 (0.4-7.3) 1.2 (0.3-14.6) 0.015
CRP (mg/dL) 6.9 (0.01-50.0) 8.1 (0.02-29.8) 15.5 (0.23-17.9) 13.1 (0.3-30.6) 0.001
Cr (mg/dL) 0.8 (0.30-9.1) 0.9 (0.4-10.1) 0.8 (06-9.3) 0.9 (0.4-5.1) <0.001
PT-INR 1.1 (0.9-1.8) 1.1 (0.9-4.1) 1.2 (1.0-1.6) 1.7 (1.1-2.1) <0.001
Table 5. Patient characteristics of no-AT, SAPT, DAPT, and AC±APT groups. Data are presented as the 
percentage or median value of parameters [range].
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Discussion
TG18 provides diagnostic criteria, a severity grading scale and a flowchart for the management of acute cholecys-
titis1,2. They recommend early LC for Grade I, II and III acute cholecystitis under strict criteria. However optimal 
management for patients remains unclear.
Recommendations regarding the management of AT in patients undergoing invasive procedures have been 
reported. Those recommendations show the bleeding risk of procedures and the timing of cessation or resump-
tion of AT during elective procedures3. When urgent or emergent procedures are required in patients taking 
warfarin, administration of reversal agents, such as vitamin K or FFP, is recommended. However, advice has been 
lacking regarding the management of antiplatelet therapy in patients undergoing emergent procedures.
For patients on AT, the most severe morbidity is perioperative hemorrhage and thrombosis. Patients on AT 
are clearly in a potentially hemorrhagic state. Our study showed significant differences in intraoperative blood 
loss and rate of RBC transfusion between the AT and no-AT groups. In an additional analysis, the AC ± APT 
group displayed a significantly higher PT-INR than other groups, and greater intraoperative blood loss than 
the no-AT group. In this study, all patients were checked for activated partial thromboplastin time and PT-INR 
before emergent surgery. The threshold at which the risk of bleeding increases is unclear, but the risk is assumed 
to remain unelevated when PT-INR is ≤1.5 and is assumed to be elevated for PT-INR > 2.09. Thus, in patients on 
warfarin therapy with PT-INR > 1.5, we administered intravenous vitamin K or/and FFP for the reversal effects 
before surgery. All patients showing PT-INR > 1.5 were administered reversal agents before surgery. However, 
not all patients were checked to ensure PT-INR was <1.5 after administration of these reversal agents. Some 
patients might thus have displayed remnant anticoagulant effects during surgery. Significant differences were also 
seen in CRP concentrations. Risk of intraoperative bleeding depends on not only anticoagulant effects, but also 
the degree of gallbladder inflammation. Between the no-AT and AC ± APT groups, no significant differences 
were seen in rate of transfusion, morbidity or mortality. We thus considered the differences in blood loss as not 
representative of any problems in terms of postoperative course. The hemostatic ability of surgical devices has 
also improved over recent decades. Several reports have shown the useful of hemostatic ability of soft-coagulation 
system in hepatectomy or nephrectomy10–12. We often perform EC for acute cholecystitis using soft-coagulation 
systems. Intraoperative bleeding is also controllable using such surgical devices. We thus do not consider intraop-
erative bleeding as a reason to delay EC in patients on AT.
Re-initiation of AT is a major determinant of postoperative bleeding after emergency surgery. The duration of 
AT discontinuation should be as short as possible. We checked vital signs, laboratory parameters, abdominal ultra-
sonography and drainage fluid (if the patient had a drainage tube) after surgery for signs of postoperative bleeding. 
In addition, AT was resumed 24–48 h after surgery. Patients on warfarin therapy received bridging therapy with 
heparin. Using this method, we did not experience any instances of postoperative hemorrhage or thrombosis.
Several reports have described perioperative outcomes in patients with AT during elective surgery13–17. Some 
reports have described laparoscopic cholecystectomy in patients on antiplatelet therapy18–21. Randomized trials 
have also reported the effects of continued aspirin on various perioperative factors22–24. Devereaux et al. reported 
that perioperative use of aspirin increased major bleeding risk in patients undergoing noncardiac surgery (aspi-










(n = 46) P
Intraoperative
Operation time, min 103 (27-263) 109 (48-346) 114 (60-208) 115 (42-306) 0.477
Blood loss, mL 10 (0-4880) 50 (0-2315) 75 (0-850) 114 (0-1300) 0.019
Laparoscopic surgery (%) 306 (86.2) 48 (85.7) 17 (81.0) 33 (71.7) 0.086
RBC transfusion (%) 9 (2.5) 5 (8.9) 4 (19.0) 1 (2.2) 0.002
Postoperative
Morbidity (CD grade ≥IIIa) (%) 13 (3.7) 5 (8.9) 0 (0) 3 (6.5) 0.201
MOF 4 0 0 0
Respiratory failure 1 0 0 0
Acute heart failure 0 0 0 1
Bile leakage 3 2 0 1
Intraabdominal abscess 3 1 0 0
Cardiac arrythmia 1 1 0 0
Pleural effusion 0 1 0 0
NOMI 1 0 0 1
Hemorrhagic complication 0 0 0 0
Thrombotic complication 0 0 0 0
Length of stay, days 6 (1-82) 7 (3-49) 7 (3-15) 8 (2-55) 0.002
30-day mortality (%) 5 (1.4) 0 (0) 0 (0) 2 (4.3) 0.351
Table 6. Perioperative outcomes for no-AT, SAPT, DAPT, and AC±APT groups. Data are presented as 
the percentage or median value of parameters [range]. MOF, multiple organ failure; NOMI, non-occlusive 
mesenteric ischemia. Multiple comparisons are shown in Fig. 1.
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AT can be classified into APT and ACT. APT is known as the most effective treatment for preventing cardi-
ovascular and cerebrovascular events. Lifelong oral administration is thus recommended for patients who have 
experienced cardiovascular or cerebrovascular events25–27. Some reports have shown that discontinuation of APT 
among patients with coronary artery or cerebrovascular disease increases the risk of major adverse events22. In 
our study, many patients in the DAPT group underwent percutaneous coronary intervention (PCI) because of 
ischemic heart disease. Although no significant differences were seen in preoperative Hb or intraoperative blood 
P <0.001























Male: sex Gallstone Severity Grade I Severity Grade
III
ASA-PS ≥3 RBC transfusion












Figure 1. Multiple comparisons of characteristics and perioperative outcomes for no-AT, SAPT, DAPT, and 
AC±APT groups. (A) Fisher’s exact test and Bonferroni correction were used for comparing categorical 
variables. (B) Continuous variables were analyzed using the Mann-Whitney U test and multiple comparisons 
were performed using the Kruskal-Wallis and Steel-Dwass tests.
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loss between the no-AT and DAPT groups, the rate of transfusion was significantly higher in the DAPT group. 
Four patients who received intraoperative transfusion in the DAPT group had undergone open cholecystec-
tomy because of severe inflammation around the gallbladder, and those patients suffered substantial blood loss 
(median, 433 mL). For DAPT cases in which open surgery is selected, more precise procedures and preparation 
of transfusion before surgery may be warranted. Importantly, our study showed no cardiovascular or cerebrovas-
cular events after emergent surgery. This may be associated with no discontinuation of antiplatelet agents.
Anticoagulant therapy is used for patients with a mechanical heart valve, nonvalvular atrial fibrillation or 
venous thromboembolism. In elective procedures, bridging anticoagulation is often used for patients on warfarin 
therapy. The BRIDGE trial showed that forgoing bridging anticoagulation did not result in inferior results to 
perioperative bridging with low-molecular-weight heparin in terms of preventing arterial thromboembolism, but 
did decrease the risk of major bleeding28. In our study, warfarin therapy was restarted the day after surgery, and 
bridging anticoagulation was provided for 24–48 h after surgery. Bridging anticoagulation was continued until 
the INR reached the therapeutic range. Direct oral anticoagulant therapy was resumed 24–48 h after surgery with-
out bridging anticoagulation. Whether bridging anticoagulation is beneficial thus remains uncertain. However, 
no hemorrhagic or thrombotic morbidity was encountered in our study. We thought that longer hospital stays in 
the AT ± APT group were due to management with anticoagulant drugs. According to TG18, Grade III cholecys-
titis is associated with hepatic dysfunction (PT-INR > 1.5). Patients displayed a high PT-INR because of warfarin 
therapy were classified as Grade III regardless of the degree of systemic inflammation. We considered this to be 
the reason why the AT group and AC ± APT group had more Grade III patients and higher PT-INR value than 
the other groups.
A few patients taking Direct Oral Anti Coagulants (DOACs) were included in this study. The half-lives of 
DOACs are shorter than that of warfarin29, and that of DOACs applied in this study ranged from 5 to 17 h30. In all 
cases, the interval time from last oral intake to emergent surgery was more than 12 h, so anticoagulant action was 
expected to decrease over time. In this study, since no parameters indicative of the anticoagulant effect of DOACs 
were examined, we cannot rule out the possibility that some anticoagulant effect of DOACs remained and affected 
outcomes for the AC ± APT group. We did not use new reversal agents, such as idarucizumab. The safety and 
utility of DOACs have been shown in comparison with warfarin, and increased use of DOAC is expected in the 
future31. And new reversal agents will play an increasingly role in emergent surgery.
In the AC ± APT group, 8 patients received combined APT and ACT. Several reports have evaluated bleeding 
risk in patients with combined APT and ACT32–34. However, in emergent surgery, the bleeding risk of combined 
therapy with reversed anticoagulant effect remains unclear. In our study, combined therapy did not increase 
intraoperative blood loss compared to anticoagulant monotherapy (100 mL vs. 130 mL, respectively; P = 0.699), 
but the small sample size limits our ability to draw conclusions on how combined therapy affected outcomes for 
the AC ± APT group. Future work would ideally deal with these issues separately.
In our study, we had a case with significant blood loss. Patient with 4880 mL of the max blood loss in the 
no-AT group had Child-Pugh class C liver cirrhosis and had coagulopathy (PT-INR = 1.62) and thrombocyto-
penia (Plt = 7.7 × 104/µL). Several reports showed safety and feasibility of cholecystectomy in patient with liver 
cirrhosis35,36. Median blood loss of 12 patients with liver cirrhosis in the no-AT group was 30 mL, and case with 
significant blood loss was unusual. But for patients with coagulopathy associated with liver cirrhosis, more precise 
indications, procedures and preparation of transfusion before surgery may be warranted as previous reports35,36. 
Even when the patient with this outlier were excluded, the analysis results were comparable.
Our study has certain limitations that need to be considered when interpreting the results. First, this study 
was a retrospective study design using a relatively small number of patients from a single center. This weakened 
validity of the statistical analysis and conclusions. However, given that few reports have considered EC on AT18–21, 
our findings appear valuable in that we evaluated more than 100 patients on multiple antithrombotic agents 
including antiplatelets and anticoagulants. A larger, well-designed, multicenter, randomized controlled trial is 
thus needed. Second, we treated various patients using antithrombotic agents as one group, further divided into 
four subgroups. However, antithrombotic effects differ between specific agents. Several agents were used in only 
a few cases, and further subgroup analysis is not feasible for this study. If more cases could be accumulated, we 
would be better able to clarify these situations. Third, although the criteria for EC indications or perioperative 
antithrombotic therapy managements were clear, no clear protocol was set for intraoperative transfusion or indi-
cations for conversion to open surgery. Patients on antithrombotic therapy display various comorbidities, and 
general condition during emergent surgery varies greatly from patient to patient. This makes it difficult to unify 
intraoperative management and we had to entrust intraoperative decisions to surgeons and anesthesiologists. 
Fourth, no cases in the present study had undergone gallbladder drainage, so we could not perform comparisons 
with elective cholecystectomy after gallbladder drainage.
In conclusion, emergent cholecystectomy appears safe to perform for acute cholecystitis in patients on AT 
thanks to the advances in surgical techniques and devices, and improvements to the perioperative management 
of AT.
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